CFR section

21 CFR 314.80(f)(1): Postmarketing reporting of adverse drug experiences

PART 314-APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG · Subpart B-Applications

Key facts

Citation 21 CFR 314.80(f)(1)
Section Postmarketing reporting of adverse drug experiences
Part PART 314-APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart Subpart B-Applications
Subchapter 21 CFR D Drugs Human
Product types cited Drugs
Regulation text (excerpt) (1) Patient information. (i) Patient identification code; (ii) Patient age at the time of adverse drug experience, or date of birth; (iii) Patient gender; and (iv) Patient weight.

At a glance

  • 10–99 Inspections citing this section
  • None Warning letters citing this section

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About CFR sections cited by the FDA

Title 21 of the Code of Federal Regulations contains the FDA's regulations, including current good manufacturing practice and quality system requirements that inspections cite.

Source: U.S. Code of Federal Regulations (eCFR); citation statistics from FDA inspection and warning-letter data

Browse all CFR sections cited by the FDA